Multidrug-Resistant Gram-Negative Infections Pipeline Insight, 2025: Tackling Escalating Resistance with Next-Gen Antibacterials | DelveInsight

DelveInsight's "Multidrug-Resistant Gram-Negative Infections - Pipeline Insight, 2025" report delivers an in-depth analysis of the dynamic R&D landscape targeting MDRGN pathogens such as Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter species. The report covers over 10 promising investigational therapies in various stages of development, including β-lactam/β-lactamase inhibitor combinations, novel tetracyclines, polymyxins, and non-traditional antibacterial agents.

As antimicrobial resistance surges globally, pharma and biotech innovators are shifting focus toward new mechanisms of action, such as outer membrane protein targeting, efflux pump inhibition, and pathogen-specific monoclonal antibodies. Notable candidates include cefepime-taniborbactam, SPR206, and QPX7728-based combinations, which are showing activity against carbapenem-resistant and extended-spectrum β-lactamase-producing organisms.

The pipeline also includes agents designed for enhanced lung penetration and reduced nephrotoxicity, addressing key challenges in treating ventilator-associated pneumonia, bloodstream infections, and complicated urinary tract infections. Companies such as Venatorx, Spero Therapeutics, Innoviva Specialty Therapeutics, and Nabriva are leading the charge with programs supported by global AMR funding initiatives.

The report explores the clinical and regulatory progress of each candidate, identifies resistance trends, and examines opportunities for hospital-based therapies, diagnostics, and stewardship-driven development. With antimicrobial innovation regaining momentum, the MDRGN pipeline offers renewed hope for combating life-threatening, drug-resistant infections.

Interested in learning more about the current treatment landscape and the key drivers shaping the multidrug-resistant gram-negative infection pipeline? Click here: https://www.delveinsight.com/report-store/multidrug-resistant-gram-negative-mdrgn-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Multidrug-Resistant Gram-Negative Infection Pipeline Report
• DelveInsight's multidrug-resistant gram-negative infection pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for multidrug-resistant gram-negative infection treatment.
• The leading multidrug-resistant gram-negative infection companies include Entasis Therapeutics Inc., SuperTrans Medical, Telum Therapeutics, ContraFect, Spero Therapeutics, AGILeBiotics, Bioharmony Therapeutics Inc., Qpex Biopharma, and others are evaluating their lead assets to improve the multidrug-resistant gram-negative infection treatment landscape.
• Key multidrug-resistant gram-negative infection pipeline therapies in various stages of development include ETX0462, CF-370, Gram-negative Lysins, SPR206, QPX9003, and others.
• In February 2025, the FDA approved EMBLAVEO (Aztreonam + Avibactam) for adults with complicated intra-abdominal infections caused by drug-resistant Gram-negative pathogens, including E. coli, Klebsiella, Enterobacter, Citrobacter, and Serratia.
• In March 2025, FDA Approves BLUJEPA, a novel oral antibiotic for uncomplicated urinary tract infections in females aged 12 and older, an important step to combat rising Gram-negative resistance.

Request a sample and discover the recent breakthroughs happening in the multidrug-resistant gram-negative infection pipeline landscape at https://www.delveinsight.com/report-store/multidrug-resistant-gram-negative-mdrgn-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multidrug-Resistant Gram-Negative Infection Overview
Multidrug-resistant Gram-negative infections are caused by bacteria that are resistant to multiple antibiotics, including critical last-line treatments like carbapenems and cephalosporins. These pathogens, such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, pose a significant threat in healthcare settings, where they can cause severe infections including pneumonia, bloodstream infections, urinary tract infections, and wound infections. Their resistance mechanisms, including extended-spectrum beta-lactamases (ESBLs) and carbapenemases, make them especially hard to treat.

The rise of MDRGN infections has outpaced the development of new antibiotics, creating an urgent need for novel treatments. Current therapeutic strategies rely on combinations of older drugs, newer beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime-avibactam), and investigational agents. Global efforts are underway to accelerate antibiotic R&D, improve diagnostics, and implement stewardship programs to curb resistance and protect existing therapies.

Find out more about multidrug-resistant gram-negative infection medication at https://www.delveinsight.com/report-store/multidrug-resistant-gram-negative-mdrgn-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multidrug-Resistant Gram-Negative Infection Treatment Analysis: Drug Profile
ETX0462: Entasis Therapeutics
ETX0462 is a first-in-class diazabicyclooctane antibiotic being developed by Entasis Therapeutics to combat multidrug-resistant (MDR) Gram-negative and biothreat pathogens, including Pseudomonas aeruginosa, Klebsiella pneumoniae, Stenotrophomonas maltophilia, E. coli, Bacillus anthracis, Yersinia pestis, Francisella tularensis, and Burkholderia species. The compound targets penicillin-binding proteins crucial for bacterial cell wall synthesis, similar to β-lactams, but uniquely remains unaffected by β-lactamase-mediated resistance. ETX0462 is currently backed by CARB-X support.

CF-370: ContraFect Corporation
CF-370 is a next-generation engineered lysin designed to treat infections caused by P. aeruginosa, a challenging Gram-negative pathogen. Unlike native lysins, which typically cannot penetrate the outer membrane of Gram-negative bacteria, CF-370 has been optimized to overcome this barrier, demonstrating potent bactericidal activity in human serum and animal models. Preclinical studies show CF-370's ability to rapidly kill bacteria, work synergistically with standard antibiotics, and effectively eliminate biofilms, hallmark features of the lysin class.

Learn more about the novel and emerging multidrug-resistant gram-negative infection pipeline therapies at https://www.delveinsight.com/report-store/multidrug-resistant-gram-negative-mdrgn-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multidrug-Resistant Gram-Negative Infection Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Multidrug-Resistant Gram-Negative Infection Pipeline Report
• Coverage: Global
• Key Multidrug-resistant Gram-negative Infection Companies: Entasis Therapeutics Inc., SuperTrans Medical, Telum Therapeutics, ContraFect, Spero Therapeutics, AGILeBiotics, Bioharmony Therapeutics Inc., Qpex Biopharma, and others.
• Key Multidrug-resistant Gram-negative Infection Pipeline Therapies: ETX0462, CF-370, Gram-negative Lysins, SPR206, QPX9003, and others.

To dive deep into rich insights for drugs used for multidrug-resistant gram-negative infection treatment, visit: https://www.delveinsight.com/report-store/multidrug-resistant-gram-negative-mdrgn-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Multidrug-Resistant Gram-Negative Infection Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Multidrug-Resistant Gram-Negative Infection Pipeline Therapeutics
6. Multidrug-Resistant Gram-Negative Infection Pipeline: Late-Stage Products (Phase III)
7. Multidrug-Resistant Gram-Negative Infection Pipeline: Mid-Stage Products (Phase II)
8. Multidrug-Resistant Gram-Negative Infection Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.